Michael Blackton has served as Senior Vice President of Cell Therapy Manufacturing since September 2021. Prior to joining Nurix, Mr. Blackton was Vice President of Quality at Adaptimmune Therapeutics where he was responsible for the development of a multi-national quality organization supporting cell therapy and lentiviral vector manufacturing. Mr. Blackton is a Board Member of the Parenteral Drug Association, a global trade organization, where he chairs the Advanced Therapy Medicinal Products Advisory Board and is a member of the Biopharmaceutical Advisory Board. Prior to 2015, Michael worked in a variety of roles at Eli Lilly and Company, ImClone Systems, Millennium Pharmaceuticals, Inhale Therapeutics, and IDEC Pharmaceuticals. Michael has extensive global regulatory inspection experience and has been directly involved in the worldwide regulatory submission, pre-approval inspection, and launch of six biologic products, two small molecule products, and one medical device. Mr. Blackton has a Bachelor of Arts Degree in Biochemistry/Cell Biology from the University of California at San Diego, and an M.B.A. with specializations in Leadership, Finance and Strategy from New York University.